These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 30791218)

  • 1. The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta-analysis.
    Xie W; Xie L; Song X
    Cancer Med; 2019 Mar; 8(3):1218-1231. PubMed ID: 30791218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic and prognostic value of blood samples for KRAS mutation identification in lung cancer: a meta-analysis.
    Shen H; Che K; Cong L; Dong W; Zhang T; Liu Q; Du J
    Oncotarget; 2017 May; 8(22):36812-36823. PubMed ID: 28415658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnostic accuracy of digital PCR, ARMS and NGS for detecting KRAS mutation in cell-free DNA of patients with colorectal cancer: A systematic review and meta-analysis.
    Ye P; Cai P; Xie J; Wei Y
    PLoS One; 2021; 16(3):e0248775. PubMed ID: 33770081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of mutations in circulating cell-free DNA in relation to disease stage in colorectal cancer.
    Liebs S; Keilholz U; Kehler I; Schweiger C; Haybäck J; Nonnenmacher A
    Cancer Med; 2019 Jul; 8(8):3761-3769. PubMed ID: 31134762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis.
    Luo J; Shen L; Zheng D
    Sci Rep; 2014 Sep; 4():6269. PubMed ID: 25201768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of PIK3CA, KRAS, BRAF, and APC hotspot mutations as a non-invasive detection method for colorectal cancer.
    Alizadeh-Sedigh M; Mahmoodzadeh H; Fazeli MS; Haddadi-Aghdam M; Teimoori-Toolabi L
    Mol Cell Probes; 2022 Jun; 63():101807. PubMed ID: 35296442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer.
    Yang X; Zhang K; Zhang C; Peng R; Sun C
    BMC Cancer; 2019 May; 19(1):465. PubMed ID: 31101027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic performance of various liquid biopsy methods in detecting colorectal cancer: A meta-analysis.
    Zhu Y; Yang T; Wu Q; Yang X; Hao J; Deng X; Yang S; Gu C; Wang Z
    Cancer Med; 2020 Aug; 9(16):5699-5707. PubMed ID: 32628360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples.
    Vivancos A; Aranda E; Benavides M; Élez E; Gómez-España MA; Toledano M; Alvarez M; Parrado MRC; García-Barberán V; Diaz-Rubio E
    Sci Rep; 2019 Jun; 9(1):8976. PubMed ID: 31222012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.
    Spindler KL; Pallisgaard N; Appelt AL; Andersen RF; Schou JV; Nielsen D; Pfeiffer P; Yilmaz M; Johansen JS; Hoegdall EV; Jakobsen A; Jensen BV
    Eur J Cancer; 2015 Nov; 51(17):2678-85. PubMed ID: 26508156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor DNA is effective for detection of KRAS mutation in colorectal cancer: a meta-analysis.
    Tang M; Deng Z; Li B; Peng Y; Song M; Liu J
    Int J Biol Markers; 2017 Oct; 32(4):e421-e427. PubMed ID: 28885658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis.
    Lin Z; Neiswender J; Fang B; Ma X; Zhang J; Hu X
    Oncotarget; 2017 Apr; 8(16):26625-26636. PubMed ID: 28460452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of circulating tumor DNA for detection of KRAS gene mutations in colorectal cancer patients: a meta-analysis.
    Hao YX; Fu Q; Guo YY; Ye M; Zhao HX; Wang Q; Peng XM; Li QW; Wang RL; Xiao WH
    Onco Targets Ther; 2017; 10():945-953. PubMed ID: 28243130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing.
    Kang JK; Heo S; Kim HP; Song SH; Yun H; Han SW; Kang GH; Bang D; Kim TY
    PLoS One; 2020; 15(5):e0232754. PubMed ID: 32379795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis.
    Zhuang R; Li S; Li Q; Guo X; Shen F; Sun H; Liu T
    PLoS One; 2017; 12(8):e0182562. PubMed ID: 28796802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer.
    Kuo YB; Chen JS; Fan CW; Li YS; Chan EC
    Clin Chim Acta; 2014 Jun; 433():284-9. PubMed ID: 24685572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of Somatic Mutations with ddPCR from Liquid Biopsy of Colorectal Cancer Patients.
    Zmrzljak UP; Košir R; Krivokapić Z; Radojković D; Nikolić A
    Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33669856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy.
    Yamada T; Matsuda A; Takahashi G; Iwai T; Takeda K; Ueda K; Kuriyama S; Koizumi M; Shinji S; Yokoyama Y; Ohta R; Yoshida H
    Int J Clin Oncol; 2020 Aug; 25(8):1523-1532. PubMed ID: 32394048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An improved digital polymerase chain reaction protocol to capture low-copy KRAS mutations in plasma cell-free DNA by resolving 'subsampling' issues.
    Ono Y; Sugitani A; Karasaki H; Ogata M; Nozaki R; Sasajima J; Yokochi T; Asahara S; Koizumi K; Ando K; Hironaka K; Daito T; Mizukami Y
    Mol Oncol; 2017 Oct; 11(10):1448-1458. PubMed ID: 28691390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
    Ai B; Liu H; Huang Y; Peng P
    Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.